11:46 AM
 | 
Oct 06, 2017
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Abivax's ABX464 reduces HIV DNA in CD4+ T cells in Phase IIa

Abivax S.A. (Euronext:ABVX) reported top-line data from 9 HIV-infected patients in the first cohort of the open-label, Spanish Phase IIa ABX464-005 trial showed that once-daily 150 mg oral ABX464 for 28 days plus antiretroviral therapy (ART) significantly reduced median HIV DNA levels in patients’ peripheral blood CD4+ T cells compared to baseline (116 vs. 191 copies/million CD4+ T cells, p<0.01). The company said that "because...

Read the full 301 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >